For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.
For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.
> For once, this isn’t hyperbole.
Am I missing something?
From other sources:
> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.
Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.
Doubling life expectancy on a form of cancer infamous as a death sentence.
In case others are wondering, it looks like this is a different story than this recent one:
Pancreatic cancer halted by virus injection in three patients - https://news.ycombinator.com/item?id=50563066 - Nov 2026 (157 comments)